MOXYVERA 625 LB

Introduction

MOXYVERA 625 LB is a prescription medicine containing Amoxycillin 500 mg, Clavulanic Acid 125 mg, and Lactobacillus 60 Million Spores, a scientifically established combination designed to treat a broad range of susceptible bacterial infections while supporting intestinal microbial balance during antibiotic therapy.

The active ingredients in MOXYVERA 625 LB work synergistically to enhance antibacterial efficacy. Amoxycillin is a broad-spectrum penicillin antibiotic that inhibits bacterial cell wall synthesis, while Clavulanic Acid is a β-lactamase inhibitor that protects Amoxycillin from enzymatic degradation by resistant bacteria, thereby extending its antibacterial spectrum. Lactobacillus acts as a probiotic, helping maintain healthy intestinal flora and supporting gastrointestinal health during antibiotic treatment.

When prescribed appropriately, MOXYVERA 625 LB provides effective treatment of common community-acquired bacterial infections while helping maintain gut microbiota during the course of therapy.

Uses of MOXYVERA 625 LB

MOXYVERA 625 LB is indicated for the treatment of bacterial infections caused by susceptible microorganisms.

It may be prescribed for:

1. Upper and lower respiratory tract infections
2. Ear, nose, and throat (ENT) infections
3. Dental and periodontal (gum) infections
4. Skin and soft tissue infections
5. Urinary tract infections (UTIs)
6. Biliary tract infections
7. Animal and human bite wound infections
8. Other bacterial infections caused by organisms susceptible to Amoxycillin-Clavulanic Acid

Note: MOXYVERA 625 LB is not effective against viral infections, including the common cold or influenza.

Benefits of MOXYVERA 625 LB

MOXYVERA 625 LB combines a broad-spectrum antibiotic, a β-lactamase inhibitor, and a probiotic to provide effective infection management with gastrointestinal support.

Scientific benefits include:

1. Provides broad-spectrum antibacterial activity against susceptible Gram-positive and Gram-negative bacteria.
2. Clavulanic Acid protects Amoxycillin from β-lactamase-mediated degradation, improving activity against resistant bacteria.
3. Effectively treats common respiratory, ENT, dental, skin, urinary, and soft tissue bacterial infections.
4. Helps eliminate susceptible bacteria by inhibiting bacterial cell wall synthesis.
5. Lactobacillus supports healthy intestinal microbiota during antibiotic therapy.
6. May reduce the risk of antibiotic-associated gastrointestinal disturbances, including diarrhea.
7. Convenient combination formulation may improve treatment adherence.
8. Supports evidence-based antimicrobial therapy when prescribed according to antimicrobial stewardship principles.

How MOXYVERA 625 LB Works

MOXYVERA 625 LB works through the complementary actions of Amoxycillin, Clavulanic Acid, and Lactobacillus.

Amoxycillin is a broad-spectrum β-lactam antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs). This weakens the bacterial cell wall, leading to bacterial death.

Some bacteria produce β-lactamase enzymes, which can inactivate Amoxycillin. Clavulanic Acid inhibits many of these enzymes, protecting Amoxycillin from degradation and restoring its antibacterial activity against β-lactamase-producing susceptible organisms.

Lactobacillus is a beneficial probiotic that helps maintain the normal balance of intestinal microorganisms during antibiotic therapy. This supports digestive health and may reduce disturbances of the gut microbiota associated with antibiotic use.

Together, these complementary mechanisms enable MOXYVERA 625 LB to effectively treat susceptible bacterial infections while supporting gastrointestinal well-being.

Dosage & Administration

MOXYVERA 625 LB should be taken only under the supervision of a qualified healthcare professional.

General Adult Dosage

1. The dosage depends on the type, severity, and site of infection, as prescribed by the treating physician.
2. The tablet is generally recommended to be taken at the start of a meal, which improves the absorption of Clavulanic Acid and may reduce gastrointestinal side effects.
3. Tablets should be swallowed whole with water.
4. The full prescribed course should be completed, even if symptoms improve earlier, to reduce the risk of treatment failure and antimicrobial resistance.
5. Patients should maintain adequate hydration during treatment.

Possible Side Effects

Like all medicines, MOXYVERA 625 LB may cause side effects, although many patients tolerate treatment well.

The more commonly reported side effects include:

1. Diarrhea
2. Nausea
3. Vomiting
4. Abdominal discomfort
5. Indigestion
6. Mild skin rash
7. Headache

Patients should seek medical advice if they develop persistent diarrhea, severe allergic reactions, extensive skin rash, difficulty breathing, or signs of liver dysfunction such as yellowing of the skin or eyes.

Contraindications & Precautions

MOXYVERA 625 LB should not be used in patients with:

1. Known hypersensitivity to Amoxycillin, Clavulanic Acid, penicillin antibiotics, Lactobacillus, or any component of the formulation.
2. A history of cholestatic jaundice or hepatic dysfunction associated with Amoxycillin-Clavulanic Acid therapy.
3. Severe immediate hypersensitivity reactions to β-lactam antibiotics (including cephalosporins where clinically relevant).

Important Precautions

MOXYVERA 625 LB should be used with caution in patients with:

1. Hepatic impairment.
2. Renal impairment requiring dosage adjustment.
3. Infectious mononucleosis, due to an increased likelihood of rash with Amoxycillin.
4. A history of antibiotic-associated colitis.
5. Patients receiving anticoagulants or other medicines that may interact with Amoxycillin-Clavulanic Acid.
6. Pregnancy or breastfeeding, only if considered appropriate by the treating physician.

Patients should inform their healthcare provider about all prescription medicines, over-the-counter medicines, and herbal supplements they are taking before starting MOXYVERA 625 LB.

Disclaimer

The information provided on this page is intended for educational purposes only and should not replace professional medical advice, diagnosis, or treatment. MOXYVERA 625 LB is a prescription medicine and should be used only under the supervision of a qualified healthcare professional. Patients should always follow their physician's advice regarding dosage, duration of treatment, and monitoring. Appropriate antibiotic use should be guided by clinical evaluation, culture and susceptibility data where available, and antimicrobial stewardship principles.